Risk-Adapted Treatment Strategy for Metastatic Prostate Cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.
This study tests a personalized treatment approach for men with metastatic prostate cancer that responds to hormone therapy. The trial aims to tailor your treatment based on disease risk level, potentially reducing side effects while maintaining effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic prostate cancer that responds to hormone-lowering therapy (castrate sensitive)
- You are a candidate for standard prostate cancer treatment according to your doctor
- You can take oral medications and comply with follow-up appointments
- You have not received other chemotherapy drugs besides docetaxel, or radiation therapy within 2 weeks
- You have not been in another clinical trial with investigational drugs in the past 28 days
- You do not have cancer spread to the brain's protective membrane (leptomeningeal disease)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
This trial is testing if removing the prostate with surgery, after starting hormone therapy, helps men with advanced prostate cancer that has spread to many parts of the body. It aims to see if this approach improves outcomes compared to hormone therapy alone.
This study tests combining targeted radiation therapy (guided by special imaging) with a hormone-blocking medication called darolutamide in men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination works better than standard treatment alone.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This study tests if a smartphone-based tracking system can help doctors decide when to change treatment for men with hormone-sensitive prostate cancer that has spread. It uses standard drugs (relugolix and an ARPI) and monitors PSA levels closely.
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.